Vision and strategy

In recent years, the research funded by FIMA has given rise to a series of patents that protect the commercial exploitation of a series of products of potential therapeutic and diagnostic use.

Digna Biotech was created with the goal of continuing this research to develop potential therapeutic and diagnostic applications.

Consequently, the first specific aims of the company may be summarized as follows:

• To obtain the necessary information on the protected products in order to document their biological effects or diagnostic properties with a view to clinical or laboratory use.
• To seek the productive and commercial partners required to register and market the products that belong to the company.
• To establish licensing agreements for our products with companies that possess marketing capacity – as this is the instrument required to obtain profits in return for the investments made.

Thus, the company selects projects on the basis of their commercial viability, and plans their development to advance towards the marketing process.

CIMA is committed to offering high quality research. The development of a system allowing interaction with the research centre in a more effective and synergistic manner is the principal task of Digna Biotech. This ensures a flow of new products from research to therapy.

The proximity of Digna to the source where new knowledge is generated creates opportunities to obtein results in an early stage of research. This in turn facilitates the adequate protection of these results with strong patents, which will later be developed by Digna or licensed to other companies.